Soberman J E, Frishman W H
Montefiore Medical Center, Bronx NY.
Am Heart J. 1988 Nov;116(5 Pt 2):1422-5. doi: 10.1016/0002-8703(88)90134-2.
Celiprolol, a long-acting beta1-selective adrenergic-blocking drug with peripheral beta2-stimulatory and peripheral a2-inhibitory activities, has a unique vasodilator beta-blocker pharmacologic profile. The efficacy and safety of celiprolol in angina pectoris have been demonstrated in multiple studies that highlight its different hemodynamic properties compared with traditional beta-blockers. Celiprolol was found to be an effective antianginal agent compared with placebo. In addition, in angina and ischemia its efficacy was comparable to that of propranolol and atenolol.
